Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Dezember 2017 01:45 ET | Quelle: BIOPHYTIS SA

Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium

PARIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today...
01. November 2017 02:45 ET | Quelle: BIOPHYTIS SA

BIOPHYTIS Completes a €7.5 M Capital Increase to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases

PARIS, Nov. 01, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company focused on innovative therapeutics to restore the muscular and visual functions in diseases...
30. Oktober 2017 01:45 ET | Quelle: BIOPHYTIS SA

BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia

PARIS, Oct. 30, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today...
27. Oktober 2017 01:45 ET | Quelle: BIOPHYTIS SA

Biophytis Appoints Professor Thomas Voit to Scientific Advisory Board to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases

PARIS, France, Oct. 27, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company focused on innovative therapeutics to restore the muscular and visual functions in...
26. Oktober 2017 12:00 ET | Quelle: BIOPHYTIS SA

BIOPHYTIS: Half-Year Financial Report as of June 30, 2017

PARIS, Oct. 26, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, presents...
11. Oktober 2017 06:28 ET | Quelle: BIOPHYTIS SA

BIOPHYTIS completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates

PARIS, Oct. 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, announces...
25. September 2017 08:00 ET | Quelle: BIOPHYTIS SA

BIOPHYTIS filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia

Protocol has been adjusted according to EMA Scientific AdviceFiling in Europe will be done in the coming days PARIS, Sept. 25, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a...
08. September 2017 08:00 ET | Quelle: BIOPHYTIS SA

Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy in Preclinical Models of Duchenne Muscular Dystrophy

Biophytis announces abstract accepted at World Muscle Society international congress (3-7 October 2017, St Malo, France)Duchenne muscular dystrophy is a new Orphan indication for Sarconeos PARIS,...
16. Juni 2017 12:02 ET | Quelle: BIOPHYTIS SA

BIOPHYTIS selects SGS Life Science Services to conduct MACA-PK, clinical study of Macuneos in dry AMD

PARIS, June 16, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, has announced...
11. Mai 2017 08:00 ET | Quelle: BIOPHYTIS SA

BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia

PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it...

Vorherige Seite

Nächste Seite